Nimesul (Nimesulide)

Nimesulide works by selectively blocking the cyclooxygenase‑2 (COX‑2) enzyme, which reduces the production of prostaglandins—molecules that mediate pain, inflammation, and fever. This selective inhibition helps control symptoms while preserving COX‑1 activity that protects the stomach lining.

The exact dose of Nimesul is determined by the prescribing clinician based on the patient’s condition, age, and overall health. Healthcare providers follow local prescribing guidelines to select the appropriate strength and dosing schedule for each individual.

Safety data for Nimesul in pregnancy are limited, and the drug is generally avoided, especially in the third trimester. Breastfeeding mothers should consult their physician, as the drug may pass into milk and affect the infant.

To order Nimesul, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nimesul is a selective COX‑2 inhibitor, which may offer a lower risk of gastrointestinal irritation compared with non‑selective NSAIDs like ibuprofen or diclofenac. However, it still carries risks of liver toxicity and other serious adverse events, so clinicians weigh benefits against potential harms for each patient.

Nimesul tablets should be stored at room temperature, below 25 °C, in their original packaging. Keep them away from moisture, direct sunlight, and excessive heat to maintain product stability throughout its shelf life.

Nimesul is taken orally, usually with a full glass of water. It can be taken with or without food, but patients who experience stomach upset may benefit from taking it with meals, as advised by their healthcare professional.

The most serious risks include severe liver injury (hepatotoxicity), gastrointestinal bleeding or ulcer perforation, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored for signs of these events and discontinue the drug immediately if they occur.

Nimesul should be avoided in individuals with known hypersensitivity to nimesulide or other NSAIDs, patients with active peptic ulcer disease, severe liver impairment, advanced heart failure, and during the third trimester of pregnancy. Clinicians must assess each patient’s medical history before prescribing.